DOAC-prompted Bleeding Fatal in Some Patients, Despite Successful Reversal in Many
Despite a high rate of effective hemostasis with reversal agents following major bleeding tied to direct oral…
Anticoagulant
-
DOAC-prompted Bleeding Fatal in Some Patients, Despite Successful Reversal in Many
Despite a high rate of effective hemostasis with reversal agents following major bleeding tied to direct oral... -
Blood-Thinner Reversal Agent Works in 82% of Serious Bleeding Cases
Broader results from the ANNEXA-4 trial have confirmed that Portola Pharmaceuticals’ andexanet alfa, sold as Andexxa, can... -
NOAC Bleeding No More Dangerous than Warfarin Bleeding
Bleeding associated with the newer non-vitamin K oral anticoagulants (NOACs) is not more dangerous than that associated...
Blood-Thinner Reversal Agent Works in 82% of Serious Bleeding Cases
Broader results from the ANNEXA-4 trial have confirmed that Portola Pharmaceuticals’ andexanet alfa, sold as Andexxa, can…
NOAC Bleeding No More Dangerous than Warfarin Bleeding
Bleeding associated with the newer non-vitamin K oral anticoagulants (NOACs) is not more dangerous than that associated…
Low Risk of Brain Hemorrhage in Ground-Level Fall with Antiplatelets, Anticoagulants
Patients who take antiplatelet or anticoagulant medications have a low risk of intracranial hemorrhage (ICH) associated with…
Intracerebral Hemorrhage Outcome Doesn’t Differ by Anticoagulant
Mortality and functional outcomes in patients with anticoagulant-related intracerebral hemorrhage (ICH) do not appear to be associated…
FDA Approves Praxbind as Reversal Agent for Pradaxa
On Oct. 16, 2015, the U.S. Food and Drug Administration gave accelerated approval to Boehringer Ingelheim’s Praxbind…